ERBB2 and breast carcinoma: In recent years, molecularly targeted therapies, including endocrine inhibitors and human epidermal growth factor receptor 2 (HER2), have changed traditional breast cancer therapy through lower toxicity, improved response rates, and enhanced prognoses [38].